Lundbeck nears end of Brazilian sham litigation probe
The chief investigator for Brazil’s antitrust authority has recommended dropping an investigation into Lundbeck, due to insufficient evidence the drugmaker conducted sham litigation in an abuse of dominance on the national pharmaceuticals market.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.